Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients

Completed

• Conditions: Multiple Sclerosis; Covid19

• Registration Number: NCT04682548
• Lead Sponsor: NYU Langone Health

Brief Summary

This non-interventional, biospecimen collection study is designed to help us better understand whether MS patients have impaired immune defenses to COVID-19 infection. The potential influence of immune modulating medications for MS will be considered through these exploratory studies. This study is also designed to provide context for interpretation of anti-SARS CoV2 serologies in MS patients during convalescence from COVID-19 infection.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-12-22
• Study First Submitted QC: 2020-12-22
• Study First Posted: 2020-12-23
• Study Start: 2021-01-05
• Primary Completion: 2022-09-15
• Study Completion: 2022-09-15
• Status Verified: 2022-11
• Last Update Submitted: 2022-11-02
• Last Update Posted: 2022-11-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 920

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Seropositivie Rate Against SARS-CoV-2	Baseline, Day 0	Seropositivity rate against SARS-CoV-2 (nucleocapsid and/or spike proteins, as available) as measured by the Roche DIA antibody assay in MS patients.

Secondary Outcome Measures

Name	Time	Method
T Cell Response	Baseline, Day 0	SARS-CoV-2 specific T cells will be measured using a well-validated assay such as ELISpot (enzyme-linked immune absorbent spot) to measure T cell responses to stimulation.

Trial Locations

Locations (1)

NYU Langone Health; 🇺🇸 New York, New York, United States